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Abstract 23	  
Background: A vaccine for Chlamydia trachomatis is of urgent medical need. We explored 24	  
bioinformatic approaches to generate an immunogen against C. trachomatis that would 25	  
induce cross-serovar T cell responses as (i) CD4+ T cells have been shown in animal models 26	  
and human studies to be important in chlamydial protection, and (ii) antibody responses may 27	  
be restrictive and serovar-specific.  28	  
Methods: A consensus antigen based on over 1,500 MOMP sequences provided high epitope 29	  
coverage against the most prevalent C. trachomatis strains in silico. Having designed the T 30	  
cell immunogen, we assessed it for immunogenicity in prime-boost regimens. This consensus 31	  
MOMP transgene was delivered using plasmid DNA, Human Adenovirus-5 (HuAd5) or 32	  
modified vaccinia Ankara (MVA) vectors with or without MF59® adjuvanted recombinant 33	  
MOMP protein.  34	  
Results: Different regimens induced distinct immune profiles. The DNA-HuAd5-MVA-35	  
Protein (DAMP) vaccine regimen induced a cellular response with a Th1 biased serum 36	  
antibody response, alongside high serum and vaginal MOMP-specific antibodies. This 37	  
regimen significantly enhanced clearance against intravaginal C. trachomatis serovar D 38	  
infection in both BALB/c and B6C3F1 mouse strains. This enhanced clearance was shown to 39	  
be CD4+ T cell dependent. Future studies will need to confirm the specificity and precise 40	  
mechanisms of protection.  41	  
Conclusions: A C. trachomatis vaccine needs to induce a robust cellular response with broad 42	  
cross-serovar coverage and a heterologous prime-boost regimen may be an approach to 43	  
achieve this.  44	  
45	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Introduction 46	  
Genital chlamydial infection is the most common cause of bacterial sexually transmitted 47	  
diseases (STDs) worldwide, accounting for more than 90 million cases of STDs globally each 48	  
year (WHO, 2001). Over US$3 billion is spent annually on an estimated 4 million reported 49	  
clinical cases of genital chlamydial infections in the US alone (CDC, 2010), thus 50	  
development of a vaccine against Chlamydia trachomatis represents a significant public 51	  
health priority. A promising vaccine antigen of C. trachomatis is the major outer membrane 52	  
protein (MOMP). The MOMP antigen has been used in a range of previous pre-clinical 53	  
vaccine studies with a mixture of encouraging (Pal et al., 2001;Farris et al., 2010) and 54	  
disappointing results (Igietseme and Murdin, 2000;Sun et al., 2009). This may reflect the 55	  
high level of amino acid variability in the MOMP antigen, the basis for C. trachomatis 56	  
serotypes (Yuan et al., 1989). 57	  
 58	  
New bioinformatic approaches have been developed to account for amino acid diversity and 59	  
aid in the design of immunogens to induce cross-serovar T cell responses: these include the 60	  
design of mosaic or conserved antigen sequences. Mosaic vaccine antigens are designed with 61	  
the intent to be used in polyvalent combinations to optimise the coverage of potential T cell 62	  
epitopes (Fischer et al., 2007), for example HIV mosaic antigens increased the breadth and 63	  
potency of vaccine elicited immune responses (Barouch et al., 2010), conferring protective 64	  
responses in non-human primate models (Barouch et al., 2013). Consensus vaccine antigens 65	  
rely on a single centralised antigen designed to reduce sequence distances between the 66	  
vaccine and circulating strains by using the most common amino acid at each position of the 67	  
protein (Gaschen et al., 2002). By reducing the genetic differences between the vaccine and 68	  
the primary isolate, consensus antigens can increase the breadth of immune response (Eugene 69	  
et al., 2013).  70	  
 71	  
Here we computationally design and in silico assess both consensus and mosaic MOMP 72	  
antigens for broad T cell coverage against the C. trachomatis genital serovars D-K, for the 73	  
reasons that (a) chlamydial infections in both animal models and humans suggest a strong 74	  
protective role for CD4+ Th1-biased immune responses (Su and Caldwell, 1995;Li et al., 75	  
2008;Farris et al., 2010) and (b) that these may be supplemented by MOMP specific 76	  
antibodies able to mediate antibody-dependent cellular cytotoxicity (ADCC) (Moore et al., 77	  
2002).  78	  
 79	  
We assess the quantity and quality of the antibody and cellular response to MOMP following 80	  
different prime-boost combinations using DNA vaccines, recombinant viral vectors and 81	  
protein-in-adjuvant formulations (McKay et al., 2014). Both DNA and recombinant viral 82	  
vectors preferentially induce cellular immunity (Tregoning and Kinnear, 2014) and subunit 83	  
proteins humoral immunity: the use of different prime boost combinations can be tailored to 84	  
influence the phenotype of both arms of induced adaptive immunity. DNA vaccine vectors, 85	  
human Adenovirus 5 and MVA viral vectors have already entered phase I clinical trials, 86	  
showing safety and tolerability (Hayton et al., 2014;Nilsson et al., 2015). Research groups 87	  
have reported enhanced T cell induction through heterologous prime-boost vaccination 88	  
strategies in a range of disease models (including tuberculosis (McShane et al., 2001), HIV 89	  
(Hanke et al., 1998), HPV (van der Burg et al., 2001) and Ebola (Sullivan et al., 2000)) but 90	  
these strategies have yet to be comprehensibly investigated for C. trachomatis.  91	  
 92	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We demonstrate that different vaccination regimens when used to deliver the same MOMP 93	  
antigen via differing platforms can be configured to induce distinct immune outcomes. We 94	  
further investigate which distinct MOMP-specific immune responses are required for 95	  
enhanced C. trachomatis clearance following genital challenge in mice. We observe that a 96	  
regimen using DNA-HuAd5-MVA-Protein (DAMP) vaccines reduced bacterial load early 97	  
after infection regardless of mouse strain used, and that this enhanced clearance while 98	  
dependent upon CD4+ T cell responses may have been augmented by induced MOMP-99	  
specific antibody responses. 100	  
 101	  
Material and Methods 102	  
Bioinformatic antigen design 103	  
1,464 serovar E ompA sequences, surveyed from a total of 5,026 C. trachomatis strains 104	  
isolated in 33 distinct geographic regions from five continents were compared (Nunes et al., 105	  
2010). Phylogenetic analysis was based on the protein sequence alignment derived from 106	  
(Nunes et al., 2010), and the maximum likelihood tree was created using FastTree (Price et 107	  
al., 2009) using default settings; the figure was generated using Rainbow Tree 108	  
(www.hiv.lanl.gov). 49 distinct ompA variants were present within the serovar E sequences, 109	  
and were used in the in silico generation of the consensus MOMP (Con E) antigen sequence 110	  
for the experimental studies. The generated consensus and mosaic antigens were assessed for 111	  
their coverage against different Chlamydia MOMP variants using the Epitope Coverage 112	  
Assessment Tool EPICOVER. Full bioinformatic tool settings, a detailed description of the 113	  
method, and consensus and mosaic antigen sequence information is provided in the 114	  
Supplemental Methods and Materials (Supplementary File 1). 115	  
 116	  
Plasmid, viral vectors and recombinant protein 117	  
Mammalian codon optimised MOMP Con E antigen was synthesised by GeneArt (Invitrogen, 118	  
UK) and cloned into pcDNA3.1 (Invitrogen, UK). Con E was homologously recombined into 119	  
the E1 and E3 deleted HuAd5 genome plasmid, pAL1112 (kindly provided by Prof. Gavin 120	  
Wilkinson, Cardiff University). Con E was recombined into the MVA pox vector by the Viral 121	  
Vector Core Facility, The Jenner Institute (University of Oxford, UK). E. coli codon 122	  
optimised Con E expressed at too low a yield in BL21 E. coli, and as such a recombinant 123	  
MOMP matching C. trachomatis from serovar D/UW/Cx expressed in BL21 E. coli was 124	  
used.  125	  
 126	  
Chlamydia 127	  
C. trachomatis serovar D (strain UW-3/Cx) was provided by Dr. Frank Follmann (Statens 128	  
Serum Institut) and propagated in McCoy cells as described previously (Scidmore, 2005). 129	  
Chlamydial EBs were harvested, purified and quantified as described in (Scidmore, 2005), 130	  
and stored at -80°C in SPG buffer (Sucrose/Phosphate/Glutamic acid: 0.2 M sucrose, 20 mM 131	  
sodium phosphate and 5 mM glutamic acid).  132	  
 133	  
Mice immunisations and infections 134	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Female 6-8 weeks old, BALB/c mice (Harlan, Stornoway, UK) and female 6-8 weeks old 135	  
B6C3F1 mice (Charles River, Italy) were kept in specific-pathogen-free conditions in 136	  
accordance with the UK Home Office guidelines. All work was approved by the Imperial 137	  
College Ethical Review Process (ERP) Committee. Mice received immunisations at three-138	  
week intervals (Table 1). DNA vaccinations were at 10 µg doses, intramuscularly into the 139	  
hind quadriceps muscle in a volume of 50 µl with electroporation. Electroporation was with 5 140	  
mm electrodes at the immunisation site using an ECM 830 Square Wave Electroporation 141	  
System (BTX), with three pulses of 100 V each, followed by three pulses of the opposite 142	  
polarity with each pulse (PON) lasting 50 ms and an interpulse (POFF) interval of 50 ms. All 143	  
HuAd5 and MVA vaccinations were at dosages of 107 PFU and 106 PFU respectively. 144	  
rMOMP was administered at a dose of 10 µg in a 1:1 mixture with MF59® (an oil-in-water 145	  
emulsion adjuvant) (Novartis, Sienna, Italy) in a final volume of 50 µl for intramuscular 146	  
immunisations. Because of the multi-component immunisation regime, vehicle and vector-147	  
alone controls were not included to reflect reduce, replace and refinement practice. Seven 148	  
days prior to intravaginal infection, mice were injected subcutaneously with 2mg of DMPA 149	  
(Depo-Provera, Pfizer). For intravaginal infections, purified C. trachomatis D/UW-3/Cx EBs 150	  
were dissolved in SPG buffer to a concentration of 4x107 IFU/ml, mice were anaesthetised, 151	  
and 10 µl of the EB solution pipetted into the mouse vagina. The optimal infective dose of 152	  
4x105 IFU of C. trachomatis D/UW-3/Cx EBs per mouse was previously determined by Dr. 153	  
Frank Follmann, SSI (unpublished data) and consistent with (O'Connell et al., 2011;Picard et 154	  
al., 2012). Furthermore, bacterial clearance profiles were consistent between naïve BALB/c 155	  
and B6C3F1 mice at this infective dose (Fig S2). Unfortunately C. trachomatis E/Bour could 156	  
not be propagated to a high enough infectious titre for intravaginal infection.  157	  
  158	  
Intravaginal C. trachomatis load quantification 159	  
Vaginal swabs were obtained at 3, 7, 10 and 14 days after infection. Swabs were vortexed 160	  
with glass-beads in 500 µl SPG buffer and stored at −80°C until analysis. Infectious load was 161	  
determined as described in (Hansen et al., 2008). Inclusions were visualised by staining with 162	  
polyclonal rabbit anti-MOMP serum (provided by Dr. Frank Follmann, SSI), followed by an 163	  
Alexa 594-conjugated goat anti-rabbit H+L (Life Technologies, UK).  164	  
 165	  
Mice sampling 166	  
Tail bleeds were collected before regimen, and two weeks post each immunisation. Blood 167	  
was collected and centrifuged at 1,000 g for 10 min. The serum was harvested and stored at -168	  
20°C. To assess IFN-γ T cell responses, lymphocyte cultures from spleens were prepared as 169	  
described previously (McKay et al., 2014). Vaginal lavage was performed at the same time 170	  
points as tail bleeds, using three 25 µl washes/mouse with sterile Phosphate buffered saline 171	  
(PBS) that were later pooled. Lavage samples were incubated with protease inhibitor (Roche 172	  
Diagnostics, Germany) before centrifuging at 1,000 g for 10 min. The fluid supernatant from 173	  
these samples was harvested and stored at -20°C.  174	  
 175	  
Semi-quantitative MOMP-specific ELISA, avidity assay, and MOMP-specific IFN-γ 176	  
ELISpot  177	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A semi-quantitative immunoglobulin ELISA protocol described previously (Badamchi-Zadeh 178	  
et al., 2015) was followed. The avidity indices of serum samples were determined by their 179	  
antibody-antigen binding resistance to 8 M urea. Serum samples were pre-diluted to give an 180	  
OD450 nm readout between 1.0 and 1.5 in an ELISA and were added to MOMP antigen coated 181	  
plates. Plates were then washed three times with either PBS-T or 8 M urea in PBS-T, before 182	  
incubating with anti-mouse IgG-HRP. Samples were developed with TMB as described 183	  
above. The avidity index was calculated as the percentage of urea treated OD450 nm/ PBS-T 184	  
OD450 nm. IFN-γ ELISpot assays (Mabtech, UK) were carried out on mouse splenocytes as to 185	  
manufacturer’s instructions.  186	  
 187	  
Depletion of CD4+ T-cells 188	  
Mice were depleted of CD4+ T-cells by the i.p. route with injections of 500 µg monoclonal 189	  
anti-mouse CD4 IgG2b (clone GK1.5) (BioXcell, Cat: BE0003-1) on days -1 and +1 with 190	  
respect to day of challenge being day 0. The depletion of CD4+ T cells was verified by FACS 191	  
analysis on murine PBMC, splenocytes and vaginal tissue on day +2 using anti-CD3e PE, 192	  
anti-CD4 APC and anti-CD8a eFluor605NC antibodies (All BD Biosciences, UK).  193	  
 194	  
Statistical Analysis 195	  
All statistical analyses were carried out using Prism 6.0 (GraphPad, USA). Normality of the 196	  
data distribution was assessed using the Kolmogorov Smirnov normality test. For non-197	  
parametric data the Kruskal-Wallis test with Dunn’s multiple comparison post-test was used 198	  
to compare more than two groups, or the two-tailed Mann-Whitney test to compare two 199	  
groups. For parametric data, a one-way ANOVA was used for multiple comparisons, with 200	  
Bonferroni’s multiple comparison post-test for comparison of specific groups. P<0.05 was 201	  
considered significant (* p<0.05, ** p<0.01 and *** p<0.001). 202	  
 203	  
Results 204	  
Design and cross-serovar coverage assessment of consensus and mosaic MOMP 205	  
antigens  206	  
The worldwide prevalence of specific urogenital C. trachomatis serovars has not been fully 207	  
characterised. A literature review (PubMed) identified 13 publications describing the country 208	  
or regional serovar-specific prevalence (Lan et al., 1995;Morre et al., 2000;Suchland et al., 209	  
2003;Yamazaki et al., 2005;Gao et al., 2007;Suarkia et al., 2007;Bandea et al., 2008;Hafner 210	  
et al., 2008;Donati et al., 2009;Petrovay et al., 2009;Smelov et al., 2009;Gallo Vaulet et al., 211	  
2010;Papadogeorgakis et al., 2010). In 10 out of the 13 C. trachomatis serovar surveys 212	  
published, serovar E emerged as the most prevalent (Fig 1A). MOMP is a lead vaccine 213	  
antigen candidate for C. trachomatis, and with worldwide MOMP sequence data available 214	  
(Nunes et al., 2010) for the differing genital serovars (D-K, Da, Ia, and Ja) it was possible to 215	  
bioinformatically perform MOMP based immunogen design. We found sequences within all 216	  
serovars to be conserved, with only sporadic amino acid substitutions (Fig 1B). From our 217	  
phylogenetic analyses, C. trachomatis has quite distant species, but high levels of 218	  
conservation within a serovar. Thus this kind of phylogenetic profile lends itself more 219	  
towards a consensus antigen design approach as opposed to a single mosaic antigen design 220	  
(Fischer et al., 2007). Based on 49 published serovar E sequence variants (Nunes et al., 2010) 221	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we generated a novel MOMP consensus sequence (Con E), which fully matched the solution 222	  
for a single mosaic and was identical to the circulating C. trachomatis strain E-Bour, as well 223	  
as to 8 additional partial MOMP protein sequences from a wide variant of geographic origins 224	  
(Nunes et al., 2010). Using a single consensus antigen the potential epitope coverage of the E 225	  
serovar led to extremely high coverage (~95%) (Fig 1C). For even broader coverage, our 226	  
analyses suggest multiple mosaic antigens may be more appropriate (Fig 1C and 227	  
Supplementary File 1). 228	  
 229	  
Differences in humoral and cellular immunogenicity of C. trachomatis MOMP vaccines 230	  
following intramuscular multi-component prime-boost regimen screen 231	  
The immunogenicity of the consensus MOMP antigen was assessed in BALB/c mice 232	  
immunised in multi-component prime-boost regimens with DNA (D), HuAd5 (A), MVA (M) 233	  
and protein with the oil-in-water emulsion adjuvant MF59® (P) vaccines (Table 1). The 234	  
MF59® adjuvant has been demonstrated to induce IL-5 and IL-10 responses to the MOMP 235	  
antigen and was therefore used as a comparator to the more Th1 skewing DNA and viral 236	  
vector approaches (Knudsen et al., 2016). Serum and vaginal washes were sampled two 237	  
weeks after final immunisation. The highest MOMP-specific serum IgG concentrations were 238	  
observed after the PPP regimen (mean + SEM = 1.27 +/- 0.16 mg/ml) and the lowest from the 239	  
DDD regimen (mean + SEM = 15.4 +/- 2.54 µg/ml) (Fig 2A). Protein (+ MF59®) 240	  
immunisation significantly increased MOMP-specific serum IgG concentrations compared to 241	  
prime-boost regimen without two protein boosts. MOMP-specific vaginal IgG concentrations 242	  
were measured following the multi-component prime-boost regimens (Fig 2B). The PPP 243	  
regimen induced significantly higher MOMP-specific vaginal IgG than DDDAM, DDDA, 244	  
DDDM, DDD, AM or the naïve group (p ≤ 0.05). MOMP-specific IgA was not detectable in 245	  
the sera or vaginal washes following any of the prime-boost regimens (data not shown).   246	  
 247	  
Viral vector vaccines have been shown to induce high and long lasting cytophilic, Th1 248	  
skewed, antibody responses (Douglas et al., 2010). A correlate for Th1 and Th2 skewing of 249	  
the immune response in mice is the antigen-specific IgG2a to IgG1 ratio. MOMP-specific 250	  
serum IgG2a and IgG1 concentrations were measured by ELISA, and their ratios calculated 251	  
(Fig 2C). The highest MOMP-specific serum IgG2a:IgG1 ratio was induced following the 252	  
DAMP regimen (mean = 14.2), with the lowest ratio induced following PP (+ MF59®) 253	  
vaccination (mean = 0.0036). There was a significant statistical difference in the IgG2a:IgG1 254	  
ratios between DAMP and PPP (p ≤ 0.005) and DAMP and PP (p ≤ 0.0005, one-way 255	  
ANOVA with Bonferroni’s multiple comparison post-test). Protein only vaccine regimens 256	  
induced Th2-biased immune environments indicated by IgG2a:IgG1 ratios of less than 1 257	  
caused by high IgG1 concentrations. Vaccine regimens with a vector-based vaccine prime 258	  
consistently induced a Th1-biased, cytophilic antibody response as indicated by IgG2a:IgG1 259	  
ratios of greater than 1.  260	  
 261	  
To differentiate and qualitatively evaluate the humoral responses an avidity assay was 262	  
performed (Fig 2D). All protein free regimens had mean avidity indices of <30%, with the 263	  
DAMP and PP regimens also having low mean avidity indices. Regimens involving two 264	  
protein boosts all had avidity indices >40%, with the APP regimen inducing MOMP-specific 265	  
serum IgGs with the highest avidity (mean = 51.8%).  266	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 267	  
T cell responses were assessed one week after the final immunisation. MOMP specific IFN-268	  
γ+ T cell responses as assessed by ELISpot were induced by all prime-boost regimens, with 269	  
the DDD and AM regimens inducing the strongest T cell responses (a median of 504 and 502 270	  
SFU/106 splenocytes respectively, Fig 2E). T cell responses induced by the DDD and AM 271	  
regimens were significantly higher than those induced in the PP regimen (p ≤ 0.05). From 272	  
this we conclude that there were significant differences in both the quantity and quality of the 273	  
antibody and cellular response following the different regimens.  274	  
 275	  
Multi-component prime-boost regimens induce analogous immunogenicity profiles in 276	  
both BALB/c and B6C3F1 mice 277	  
As we wished to test the effect of altering the immune response on Chlamydial protection, the 278	  
following groups were chosen for further investigation as they gave distinct, skewed immune 279	  
responses in the BALB/c screen: AM and DDD (T cell, low antibody), PPP (Th2 skewed 280	  
antibody, no Th1 T cells), and DAMP (Th1 skewed antibody and T cell). These vaccine 281	  
regimens induced comparable responses in B6C3F1 mice as they did in BALB/c mice for 282	  
MOMP-specific serum IgG concentrations (Fig 3A), MOMP-specific vaginal IgG 283	  
concentrations (Fig 3B), MOMP-specific serum IgG2a to IgG1 ratios (Fig 3C), and MOMP 284	  
specific IFN-γ T cell responses (Fig 3D). 285	  
 286	  
The DAMP vaccine regimen enhances the clearance of C. trachomatis, regardless of 287	  
mouse strain, and is CD4+ T dependent 288	  
Immunised BALB/c mice were challenged with C. trachomatis D/UW-3/Cx intravaginally. 289	  
The DAMP regimen significantly reduced chlamydial IFU per swab at day 3 after challenge 290	  
(median = 354 IFU/swab) compared to unvaccinated controls (median = 22,688 IFU/swab) 291	  
(DAMP: * p = 0.0359, 2-tailed Mann-Whitney test) (Fig 4A). There were no statistical 292	  
differences at the later sampling points of 7, 10 and 14 days (data not shown) after challenge 293	  
reflecting the natural clearance of C. trachomatis in mice. The DDD, AM, and PPP regimens 294	  
did not significantly reduce chlamydial shedding at any time points sampled after challenge 295	  
in BALB/c mice.  296	  
 297	  
Immunised B6C3F1 mice were challenged with C. trachomatis D/UW-3/Cx intravaginally. 298	  
Similar to BALB/c mice, the DAMP vaccination regimen significantly reduced chlamydial 299	  
IFU per swab at day 3 after challenge (median = 6,531 IFU/swab) compared to unvaccinated 300	  
controls (median = 34,788 IFU/swab) (* p = 0.0303, 2-tailed Mann-Whitney test) in 301	  
B6C3F1s (Fig 4B). In addition, the PPP regimen significantly reduced chlamydial IFU per 302	  
swab at day 3 after challenge (median = 8,095 IFU/swab) compared to unvaccinated controls 303	  
(median = 34,788 IFU/swab) (* p = 0.0451, 2-tailed Mann-Whitney test) (Fig 4B). There 304	  
were no statistical differences at the later sampling points of day 7, day 10 or day 14 after 305	  
challenge, and consistent with this challenge model, there was no oviduct pathology observed 306	  
(hydrosalpinx) in challenged BALB/c or B6C3F1 mice (data not shown). Of the four tested 307	  
prime-boost regimens, only the DAMP regimen consistently enhanced the clearance of 308	  
intravaginal C. trachomatis.  309	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 310	  
We assessed the mechanism of the vaccine-induced enhanced clearance. Monoclonal 311	  
antibodies were used to deplete CD4+ T cells in DAMP vaccinated and unvaccinated control 312	  
B6C3F1 mice prior to intravaginal challenge. There was no difference between the DAMP 313	  
immunised CD4+ depleted groups and the naïve CD4+ depleted group in chlamydial loads, 314	  
indicating that the DAMP vaccine induced enhanced clearance is CD4+ T cell dependent (Fig 315	  
4C).  316	  
 317	  
Discussion 318	  
New bioinformatic strategies have been developed as an approach to elicit broad immune 319	  
responses against the more intractable antigenically variable pathogens, such as C. 320	  
trachomatis. Two such approaches, consensus and mosaic, were used to design a MOMP 321	  
antigen(s) to provide broad cellular cross-serovar coverage. We performed phylogenetic 322	  
analyses revealing C. trachomatis MOMP to have quite distant species but high levels of 323	  
amino acid conservation within a serovar. This phylogenetic structure lends itself more 324	  
towards a consensus-based antigen design as opposed to a mosaic-based approach (Fischer et 325	  
al., 2007). Therefore a single consensus MOMP antigen (Con E), constructed from variant 326	  
sequences of the most common C. trachomatis serovar, was used. Nevertheless, combining 327	  
the Con E antigen with additional mosaic antigens (that we have designed (Supplementary 328	  
Materials)) would provide complementary coverage to all other serovars. This would be a 329	  
well-justified approach to theoretically achieve comprehensive coverage of all serovars in 330	  
one vaccine, with no loss of coverage of the E serovar (Fig 1C), however assessing these 331	  
additional antigens immunologically was out of the scope of this initial study. 332	  
 333	  
Having designed our broad-coverage T cell immunogen, we then assessed its 334	  
immunogenicity using a range of prime-boost regimens. Few multi-component prime-boost 335	  
vaccine regimens have been tested for the generation of immune responses against 336	  
Chlamydia (Brown et al., 2012), with the majority focussing on homologous prime-boost 337	  
strategies (Pal et al., 2005;Schautteet et al., 2011). The use of different vectors within prime-338	  
boost regimen can help to avoid anti-vector immunity and improve vaccine-elicited immune 339	  
responses. Previous uses of DNA vaccines expressing Chlamydia transgenes have not been 340	  
adjuvanted by electroporation as in this study (Dong-Ji et al., 2000;Penttila et al., 2004), and 341	  
only one previous use of an adenovirus-vectored vaccine against Chlamydia muridarum 342	  
(expressing CPAF) has been reported (Brown et al., 2012).  343	  
 344	  
Following an initial screen of eleven prime-boost regimens, four immunologically distinct 345	  
regimens were assessed in both BALB/c and B6C3F1 mice. The AM, DDD, PPP and DAMP 346	  
regimens showed no mouse-strain specific discrepancies in the humoral or cellular responses 347	  
induced. Of these four regimens, only the DAMP vaccination regimen enhanced the 348	  
clearance of intravaginal C. trachomatis, regardless of mouse strain. This enhanced 349	  
chlamydial clearance afforded by the DAMP vaccination regimen was dependent on CD4+ T 350	  
cells, as shown by CD4+ T cell depletion following vaccination. Previous chlamydia vaccine 351	  
studies in mice have also revealed a role for CD4+ T cells in their protection, including in the 352	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liposomal delivery of rMOMP (Hansen et al., 2008) and the subcutaneous delivery of CTH1 353	  
(Olsen et al., 2010).  354	  
 355	  
The importance of IFN-γ in vivo to chlamydia control has been demonstrated previously 356	  
(Cotter et al., 1997;Ito and Lyons, 1999). In this respect it appears somewhat surprising that 357	  
the DDD and AM regimens, inducing stronger T cell IFN-γ responses than DAMP, failed to 358	  
show any evidence for enhanced clearance. However, a distinct characteristic of the DAMP 359	  
vaccination regimen was the co-induction of significantly higher levels of MOMP-specific 360	  
IgG2a (with a high IgG2a/IgG1 ratio). This was in spite of the use of the protein adjuvant 361	  
MF59®, which has previously been shown to skew T cell responses against MOMP towards 362	  
IL-5 and IL-10 (Knudsen et al., 2016); this may be explained by the order of immunisations, 363	  
with the initial MOMP antigen exposures in the context of DNA and viral vector delivery 364	  
skewing the response, as the protein-adjuvant boosted regimens resulted in a strong IgG1 365	  
bias. Chlamydial-specific IgG2a antibody concentrations have previously correlated with 366	  
protection in animal studies (Pal et al., 2001). Thus although enhanced clearance was 367	  
dependent upon CD4 T cell responses, these data suggest induced IgG2a responses may have 368	  
played a contributory role in the enhanced clearance of C. trachomatis infection. In this 369	  
respect, EB opsonisation by IgG isotypes is known to affect the uptake of chlamydia into 370	  
cells (Peterson et al., 1997). EB opsonisation with a high IgG1 and low IgG2a anti-MOMP 371	  
polyclonal sera has been shown to enhance infection of a cell line through the FcRn mediated 372	  
uptake of these IgG-coated EBs, suggesting a negative role for MOMP-specific IgG1 373	  
antibodies (Armitage et al., 2014). The IgG2a isotype by contrast mediates effector functions 374	  
including antibody-dependent cellular cytotoxicity (ADCC), with evidence suggesting this 375	  
effector function may facilitate the early clearance of a chlamydial infection (Moore et al., 376	  
2002), furthermore ADCC is associated with enhanced antigen presentation with the potential 377	  
to amplify CD4 T cell responses (Rafiq et al., 2002). Collectively, these suggest that the anti-378	  
MOMP IgG isotype may have a contributory role in the protection observed from the DAMP 379	  
regimen, though without a DAM comparator arm this would require further investigation. 380	  
 381	  
We cannot rule out that the DAMP vaccination regimen itself is in fact lowering the 382	  
establishment of infection, and thus resulting in the lower IFU observed, as our earliest 383	  
sampling point is day 3 after challenge. Moreover, we cannot exclude the possibility that non-384	  
specific effects of the vaccine components in the DAMP regimen may impact general T-cell 385	  
function. Future work should assess the potential non-specific immunologic effects of 386	  
antigen-delivery by viral vectors alongside adjuvantation during prime-boost vaccinations.   387	  
 388	  
In this study we undertook a bioinformatic approach to generate an immunogen that would 389	  
induce cross-serovar Chlamydial T cell responses. We have revealed a capability to induce an 390	  
array of MOMP-specific immune responses, both cellular and humoral, using four differing 391	  
MOMP-based vaccine modalities in multi-component prime-boost regimens. The comparison 392	  
of the same antigen by different modalities gives us insight into the distinct immune profiles 393	  
induced by these vaccines. Based on our focus of developing vaccine candidates to progress 394	  
towards clinical testing we opted to use C. trachomatis for our challenged studies, rather than 395	  
the more conventional use of C. muridarium that is pathogenic in mice. Though C. 396	  
trachomatis is not a natural pathogen of mice, it has been argued that that intravaginal 397	  
infection with C. trachomatis mimics in many ways both the course and outcome of infection 398	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in most women as asymptomatic and self-limiting (Lyons et al., 2005). In this context, the 399	  
observed significant reduction in shedding following DAMP vaccination observed 3 days 400	  
post infection is particularly encouraging given rapid natural clearance in naïve animals. We 401	  
would anticipate a greater impact on C. trachomatis clearance in transcervical infection 402	  
models, in non-human primate models, and in humans, where the infection is slow to clear 403	  
and/or may establish chronic infection and this will form the focus of our future studies.  404	  
Conflict of Interest Statement: 405	  
The authors declare no commercial or financial conflict of interest. 406	  
 407	  
Author Contributions: 408	  
AB, PM, BK, GB, AW performed the experiments; AB, PM, JT & RS designed the studies; 409	  
AN, JG, FF provided data sources. AB& JT wrote the paper. 410	  
 411	  
Funding: 412	  
AB was funded by the Wellcome Trust. RS was supported by the European Community’s 413	  
European 7th Framework Program ADITEC (HEALTH-F4-2011-18 280873). 414	  
 415	  
Acknowledgments 416	  
Thanks to GSK (Sienna) for the provision of the adjuvant MF59®, Dr. Frank Follmann 417	  
(Statens Serum Institut) for the provision of C. trachomatis D/UW-3/Cx, the University of 418	  
Oxford Viral Vector Core Facility for the construction of the MVA-MOMP virus, and Prof. 419	  
Gavin Wilkinson (University of Cardiff) for the HuAd5 genome plasmid pAL1112. Thanks 420	  
to Dr N. Provine and Dr R. Larocca (Harvard Medical School) for manuscript comments and 421	  
Dr Christopher Thompson (Imperial College London) for helping with Chlamydia 422	  
propagation.  423	  
 424	  
 425	  
References 426	  
Armitage, C.W., O'meara, C.P., Harvie, M.C., Timms, P., Blumberg, R.S., and Beagley, 427	  
K.W. (2014). Divergent outcomes following transcytosis of IgG targeting intracellular 428	  
and extracellular chlamydial antigens. Immunol Cell Biol 92, 417-426. 429	  
Badamchi-Zadeh, A., Mckay, P.F., Holland, M.J., Paes, W., Brzozowski, A., Lacey, C., 430	  
Follmann, F., Tregoning, J.S., and Shattock, R.J. (2015). Intramuscular Immunisation 431	  
with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies. 432	  
PLoS One 10, e0141209. 433	  
Bandea, C.I., Debattista, J., Joseph, K., Igietseme, J., Timms, P., and Black, C.M. (2008). 434	  
Chlamydia trachomatis serovars among strains isolated from members of rural 435	  
indigenous communities and urban populations in Australia. J Clin Microbiol 46, 436	  
355-356. 437	  
Barouch, D.H., O'brien, K.L., Simmons, N.L., King, S.L., Abbink, P., Maxfield, L.F., Sun, 438	  
Y.H., La Porte, A., Riggs, A.M., Lynch, D.M., Clark, S.L., Backus, K., Perry, J.R., 439	  
Seaman, M.S., Carville, A., Mansfield, K.G., Szinger, J.J., Fischer, W., Muldoon, M., 440	  
and Korber, B. (2010). Mosaic HIV-1 vaccines expand the breadth and depth of 441	  
cellular immune responses in rhesus monkeys. Nat Med 16, 319-323. 442	  
Barouch, D.H., Stephenson, K.E., Borducchi, E.N., Smith, K., Stanley, K., Mcnally, A.G., 443	  
Liu, J., Abbink, P., Maxfield, L.F., Seaman, M.S., Dugast, A.S., Alter, G., Ferguson, 444	  
M., Li, W., Earl, P.L., Moss, B., Giorgi, E.E., Szinger, J.J., Eller, L.A., Billings, E.A., 445	  
Rao, M., Tovanabutra, S., Sanders-Buell, E., Weijtens, M., Pau, M.G., Schuitemaker, 446	  
H., Robb, M.L., Kim, J.H., Korber, B.T., and Michael, N.L. (2013). Protective 447	  
P o
ision
l
12 
 
efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in 448	  
rhesus monkeys. Cell 155, 531-539. 449	  
Brown, T.H.T., David, J., Acosta-Ramirez, E., Moore, J.M., Lee, S., Zhong, G., Hancock, 450	  
R.E.W., Xing, Z., Halperin, S.A., and Wang, J. (2012). Comparison of immune 451	  
responses and protective efficacy of intranasal prime-boost immunization regimens 452	  
using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital 453	  
Chlamydia muridarum infection. Vaccine 30, 350-360. 454	  
Cdc (2010). Sexually Transmitted Disease Surveillance 2010. Atlanta, GA: Centers for 455	  
Disease Control and Prevention. 456	  
Cotter, T.W., Ramsey, K.H., Miranpuri, G.S., Poulsen, C.E., and Byrne, G.I. (1997). 457	  
Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma 458	  
interferon gene knockout mice. Infect Immun 65, 2145-2152. 459	  
Donati, M., Di Francesco, A., D'antuono, A., Pignanelli, S., Shurdhi, A., Moroni, A., 460	  
Baldelli, R., and Cevenini, R. (2009). Chlamydia trachomatis serovar distribution and 461	  
other concurrent sexually transmitted infections in heterosexual men with urethritis in 462	  
Italy. Eur J Clin Microbiol Infect Dis 28, 523-526. 463	  
Dong-Ji, Z., Yang, X., Shen, C., Lu, H., Murdin, A., and Brunham, R.C. (2000). Priming 464	  
with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed 465	  
by MOMP ISCOM boosting enhances protection and is associated with increased 466	  
immunoglobulin A and Th1 cellular immune responses. Infect Immun 68, 3074-3078. 467	  
Douglas, A.D., De Cassan, S.C., Dicks, M.D., Gilbert, S.C., Hill, A.V., and Draper, S.J. 468	  
(2010). Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell 469	  
responses by using combinations of adenovirus, poxvirus and protein-adjuvant 470	  
vaccines against Plasmodium falciparum MSP1. Vaccine 28, 7167-7178. 471	  
Eugene, H.S., Pierce-Paul, B.R., Cragio, J.K., and Ross, T.M. (2013). Rhesus macaques 472	  
vaccinated with consensus envelopes elicit partially protective immune responses 473	  
against SHIV SF162p4 challenge. Virol J 10, 102. 474	  
Farris, C.M., Morrison, S.G., and Morrison, R.P. (2010). CD4+ T cells and antibody are 475	  
required for optimal major outer membrane protein vaccine-induced immunity to 476	  
Chlamydia muridarum genital infection. Infect Immun 78, 4374-4383. 477	  
Fischer, W., Perkins, S., Theiler, J., Bhattacharya, T., Yusim, K., Funkhouser, R., Kuiken, C., 478	  
Haynes, B., Letvin, N.L., Walker, B.D., Hahn, B.H., and Korber, B.T. (2007). 479	  
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 480	  
variants. Nat Med 13, 100-106. 481	  
Gallo Vaulet, L., Entrocassi, C., Corominas, A.I., and Rodriguez Fermepin, M. (2010). 482	  
Distribution study of Chlamydia trachomatis genotypes in symptomatic patients in 483	  
Buenos Aires, Argentina: association between genotype E and neonatal conjunctivitis. 484	  
BMC Res Notes 3, 34. 485	  
Gao, X., Chen, X.S., Yin, Y.P., Zhong, M.Y., Shi, M.Q., Wei, W.H., Chen, Q., Peeling, 486	  
R.W., and Mabey, D. (2007). Distribution study of Chlamydia trachomatis serovars 487	  
among high-risk women in China performed using PCR-restriction fragment length 488	  
polymorphism genotyping. J Clin Microbiol 45, 1185-1189. 489	  
Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., Novitsky, V., Haynes, B., 490	  
Hahn, B.H., Bhattacharya, T., and Korber, B. (2002). Diversity considerations in 491	  
HIV-1 vaccine selection. Science 296, 2354-2360. 492	  
Hafner, L., Beagley, K., and Timms, P. (2008). Chlamydia trachomatis infection: host 493	  
immune responses and potential vaccines. Mucosal Immunol 1, 116-130. 494	  
Hanke, T., Blanchard, T.J., Schneider, J., Hannan, C.M., Becker, M., Gilbert, S.C., Hill, 495	  
A.V., Smith, G.L., and Mcmichael, A. (1998). Enhancement of MHC class I-496	  
rovis
io al
13 
 
restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination 497	  
regime. Vaccine 16, 439-445. 498	  
Hansen, J., Jensen, K.T., Follmann, F., Agger, E.M., Theisen, M., and Andersen, P. (2008). 499	  
Liposome delivery of Chlamydia muridarum major outer membrane protein primes a 500	  
Th1 response that protects against genital chlamydial infection in a mouse model. J 501	  
Infect Dis 198, 758-767. 502	  
Hayton, E.-J., Rose, A., Ibrahimsa, U., Del Sorbo, M., Capone, S., Crook, A., Black, A.P., 503	  
Dorrell, L., and Hanke, T. (2014). Safety and Tolerability of Conserved Region 504	  
Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia 505	  
Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected 506	  
Adults in a Randomized, Single-Blind Phase I Trial. PLoS ONE 9, e101591. 507	  
Igietseme, J.U., and Murdin, A. (2000). Induction of protective immunity against Chlamydia 508	  
trachomatis genital infection by a vaccine based on major outer membrane protein-509	  
lipophilic immune response-stimulating complexes. Infect Immun 68, 6798-6806. 510	  
Ito, J.I., and Lyons, J.M. (1999). Role of gamma interferon in controlling murine chlamydial 511	  
genital tract infection. Infect Immun 67, 5518-5521. 512	  
Knudsen, N.P., Olsen, A., Buonsanti, C., Follmann, F., Zhang, Y., Coler, R.N., Fox, C.B., 513	  
Meinke, A., U, D.O., Casini, D., Bonci, A., Billeskov, R., De Gregorio, E., Rappuoli, 514	  
R., Harandi, A.M., Andersen, P., and Agger, E.M. (2016). Different human vaccine 515	  
adjuvants promote distinct antigen-independent immunological signatures tailored to 516	  
different pathogens. Sci Rep 6, 19570. 517	  
Lan, J., Melgers, I., Meijer, C.J., Walboomers, J.M., Roosendaal, R., Burger, C., Bleker, 518	  
O.P., and Van Den Brule, A.J. (1995). Prevalence and serovar distribution of 519	  
asymptomatic cervical Chlamydia trachomatis infections as determined by highly 520	  
sensitive PCR. J Clin Microbiol 33, 3194-3197. 521	  
Li, W., Murthy, A.K., Guentzel, M.N., Seshu, J., Forsthuber, T.G., Zhong, G., and 522	  
Arulanandam, B.P. (2008). Antigen-specific CD4+ T cells produce sufficient IFN-523	  
gamma to mediate robust protective immunity against genital Chlamydia muridarum 524	  
infection. J Immunol 180, 3375-3382. 525	  
Lyons, J.M., Ito, J.I., Jr., Pena, A.S., and Morre, S.A. (2005). Differences in growth 526	  
characteristics and elementary body associated cytotoxicity between Chlamydia 527	  
trachomatis oculogenital serovars D and H and Chlamydia muridarum. J Clin Pathol 528	  
58, 397-401. 529	  
Mckay, P.F., Cope, A.V., Mann, J.F., Joseph, S., Esteban, M., Tatoud, R., Carter, D., Reed, 530	  
S.G., Weber, J., and Shattock, R.J. (2014). Glucopyranosyl Lipid A Adjuvant 531	  
Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-532	  
MVA-Protein Vaccine Regimen. PLoS One 9, e84707. 533	  
Mcshane, H., Brookes, R., Gilbert, S.C., and Hill, A.V. (2001). Enhanced immunogenicity of 534	  
CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus 535	  
Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 69, 536	  
681-686. 537	  
Moore, T., Ananaba, G.A., Bolier, J., Bowers, S., Belay, T., Eko, F.O., and Igietseme, J.U. 538	  
(2002). Fc receptor regulation of protective immunity against Chlamydia trachomatis. 539	  
Immunology 105, 213-221. 540	  
Morre, S.A., Rozendaal, L., Van Valkengoed, I.G., Boeke, A.J., Van Voorst Vader, P.C., 541	  
Schirm, J., De Blok, S., Van Den Hoek, J.A., Van Doornum, G.J., Meijer, C.J., and 542	  
Van Den Brule, A.J. (2000). Urogenital Chlamydia trachomatis serovars in men and 543	  
women with a symptomatic or asymptomatic infection: an association with clinical 544	  
manifestations? J Clin Microbiol 38, 2292-2296. 545	  
r vis
i al
14 
 
Nilsson, C., Hejdeman, B., Godoy-Ramirez, K., Tecleab, T., Scarlatti, G., Bråve, A., Earl, 546	  
P.L., Stout, R.R., Robb, M.L., Shattock, R.J., Biberfeld, G., Sandström, E., and 547	  
Wahren, B. (2015). HIV-DNA Given with or without Intradermal Electroporation Is 548	  
Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A 549	  
Phase I Randomized Trial. PLoS ONE 10, e0131748. 550	  
Nunes, A., Nogueira, P.J., Borrego, M.J., and Gomes, J.P. (2010). Adaptive evolution of the 551	  
Chlamydia trachomatis dominant antigen reveals distinct evolutionary scenarios for 552	  
B- and T-cell epitopes: worldwide survey. PLoS One 5. 553	  
O'connell, C.M., Abdelrahman, Y.M., Green, E., Darville, H.K., Saira, K., Smith, B., 554	  
Darville, T., Scurlock, A.M., Meyer, C.R., and Belland, R.J. (2011). Toll-like receptor 555	  
2 activation by Chlamydia trachomatis is plasmid dependent, and plasmid-responsive 556	  
chromosomal loci are coordinately regulated in response to glucose limitation by C. 557	  
trachomatis but not by C. muridarum. Infect Immun 79, 1044-1056. 558	  
Olsen, A.W., Theisen, M., Christensen, D., Follmann, F., and Andersen, P. (2010). Protection 559	  
against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary 560	  
intranasal infection in a mouse genital challenge model. PLoS One 5, e10768. 561	  
Pal, S., Peterson, E.M., and De La Maza, L.M. (2005). Vaccination with the Chlamydia 562	  
trachomatis major outer membrane protein can elicit an immune response as 563	  
protective as that resulting from inoculation with live bacteria. Infect Immun 73, 8153-564	  
8160. 565	  
Pal, S., Theodor, I., Peterson, E.M., and De La Maza, L.M. (2001). Immunization with the 566	  
Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a 567	  
protective immune response against a genital challenge. Infect Immun 69, 6240-6247. 568	  
Papadogeorgakis, H., Pittaras, T.E., Papaparaskevas, J., Pitiriga, V., Katsambas, A., and 569	  
Tsakris, A. (2010). Chlamydia trachomatis serovar distribution and Neisseria 570	  
gonorrhoeae coinfection in male patients with urethritis in Greece. J Clin Microbiol 571	  
48, 2231-2234. 572	  
Penttila, T., Tammiruusu, A., Liljestrom, P., Sarvas, M., Makela, P.H., Vuola, J.M., and 573	  
Puolakkainen, M. (2004). DNA immunization followed by a viral vector booster in a 574	  
Chlamydia pneumoniae mouse model. Vaccine 22, 3386-3394. 575	  
Peterson, E.M., Cheng, X., Motin, V.L., and De La Maza, L.M. (1997). Effect of 576	  
immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse 577	  
model of intravaginal infection. Infect Immun 65, 2693-2699. 578	  
Petrovay, F., Balla, E., Nemeth, I., and Gonczol, E. (2009). Genotyping of Chlamydia 579	  
trachomatis from the endocervical specimens of high-risk women in Hungary. J Med 580	  
Microbiol 58, 760-764. 581	  
Picard, M.D., Cohane, K.P., Gierahn, T.M., Higgins, D.E., and Flechtner, J.B. (2012). High-582	  
throughput proteomic screening identifies Chlamydia trachomatis antigens that are 583	  
capable of eliciting T cell and antibody responses that provide protection against 584	  
vaginal challenge. Vaccine 30, 4387-4393. 585	  
Price, M.N., Dehal, P.S., and Arkin, A.P. (2009). FastTree: computing large minimum 586	  
evolution trees with profiles instead of a distance matrix. Mol Biol Evol 26, 1641-587	  
1650. 588	  
Rafiq, K., Bergtold, A., and Clynes, R. (2002). Immune complex-mediated antigen 589	  
presentation induces tumor immunity. J Clin Invest 110, 71-79. 590	  
Schautteet, K., Stuyven, E., Beeckman, D.S., Van Acker, S., Carlon, M., Chiers, K., Cox, E., 591	  
and Vanrompay, D. (2011). Protection of pigs against Chlamydia trachomatis 592	  
challenge by administration of a MOMP-based DNA vaccine in the vaginal mucosa. 593	  
Vaccine 29, 1399-1407. 594	  
Prov
io al
15 
 
Scidmore, M.A. (2005). Cultivation and Laboratory Maintenance of Chlamydia trachomatis. 595	  
Curr Protoc Microbiol Chapter 11, Unit 11A 11. 596	  
Smelov, V., Quint, K.D., Pleijster, J., Savelkoul, P.H., Shalepo, K., Shipitsyna, E., Domeika, 597	  
M., Gorelov, A., Savicheva, A., Quint, W.G., De Vries, H.J., Ouburg, S., and Morre, 598	  
S.A. (2009). Chlamydia trachomatis serovar distributions in Russian men and women: 599	  
a comparison with Dutch serovar distributions. Drugs Today (Barc) 45 Suppl B, 33-600	  
38. 601	  
Su, H., and Caldwell, H.D. (1995). CD4+ T cells play a significant role in adoptive immunity 602	  
to Chlamydia trachomatis infection of the mouse genital tract. Infect Immun 63, 3302-603	  
3308. 604	  
Suarkia, D.L., Mgone, C.S., Lehmann, D., Passey, M.E., Lupiwa, T., Paniu, M.M., Kono, J., 605	  
Kakazo, M., Yeka, W., and Alpers, M.P. (2007). Chlamydia trachomatis infection and 606	  
distribution of serovars in the Eastern Highlands Province, Papua New Guinea. P N G 607	  
Med J 50, 134-144. 608	  
Suchland, R.J., Eckert, L.O., Hawes, S.E., and Stamm, W.E. (2003). Longitudinal assessment 609	  
of infecting serovars of Chlamydia trachomatis in Seattle public health clinics: 1988-610	  
1996. Sex Transm Dis 30, 357-361. 611	  
Sullivan, N.J., Sanchez, A., Rollin, P.E., Yang, Z.Y., and Nabel, G.J. (2000). Development of 612	  
a preventive vaccine for Ebola virus infection in primates. Nature 408, 605-609. 613	  
Sun, G., Pal, S., Weiland, J., Peterson, E.M., and De La Maza, L.M. (2009). Protection 614	  
against an intranasal challenge by vaccines formulated with native and recombinant 615	  
preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 616	  
27, 5020-5025. 617	  
Tregoning, J.S., and Kinnear, E. (2014). Using Plasmids as DNA Vaccines for Infectious 618	  
Diseases. Microbiology Spectrum 2. 619	  
Van Der Burg, S.H., Kwappenberg, K.M., O'neill, T., Brandt, R.M., Melief, C.J., Hickling, 620	  
J.K., and Offringa, R. (2001). Pre-clinical safety and efficacy of TA-CIN, a 621	  
recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous 622	  
prime-boost regimens. Vaccine 19, 3652-3660. 623	  
Who (2001). Global Prevalence and Incidence of Selected Curable Sexually Transmitted 624	  
Diseases: Overview and Estimates. Geneva, Switzerland: World Health Organisation. 625	  
Yamazaki, T., Hagiwara, T., Kishimoto, T., Sasaki, N., Takahashi, S., Ishihara, O., 626	  
Wangroongsarb, P., Kusum, M., and Sirivongrangsan, P. (2005). Distribution of 627	  
Chlamydia trachomatis serovars among female prostitutes and non-prostitutes in 628	  
Thailand, and non-prostitutes in Japan during the mid-90s. Jpn J Infect Dis 58, 211-629	  
213. 630	  
Yuan, Y., Zhang, Y.X., Watkins, N.G., and Caldwell, H.D. (1989). Nucleotide and deduced 631	  
amino acid sequences for the four variable domains of the major outer membrane 632	  
proteins of the 15 Chlamydia trachomatis serovars. Infect Immun 57, 1040-1049. 633	  
 634	  
635	  
Prov
is n
al
16 
 
Table 1. Multi-component prime-boost vaccine regimens. 636	  
In vaccine regimen nomenclature, D represents DNA (+ electroporation), A represents 637	  
HuAd5, M represents MVA, and P represents recombinant MOMP protein adjuvanted with 638	  
MF59®.  639	  
 640	  
 641	  
 642	  
 643	  
 644	  
 645	  
 646	  
 647	  
 648	  
 649	  
 650	  
 651	  
 652	  
 653	  
 654	  
Figure 1. Global C. trachomatis serovar prevalence, phylogeny and theoretical epitope 655	  
coverage of consensus and mosaic MOMP antigens.  656	  
(A)The serovar prevalence of C. trachomatis worldwide compiled from a literature review 657	  
and represented in descending prevalence at global locations. (B) A phylogenetic maximum 658	  
likelihood tree based on the ompA sequence alignments derived from (Nunes et al., 2010) was 659	  
created using FastTree and the graphic generated by Rainbow Tree. (C) Potential epitope 660	  
coverage against all serovars (total) and individual serovars (serovars D-K) were analysed for 661	  
a monovalent Con E antigen, Con E and Con F antigens, 2 mosaic antigens, a Con E antigen 662	  
and a mosaic antigen, three mosaic antigens and a Con E antigen with 2 additional mosaic 663	  
antigens using EPICOVER. Mean 9-mer coverage presented against individual and total 664	  
combined serovars D to K, with exact (red), off-by-1 (orange) and off-by-2 (yellow) epitope 665	  
matching.  666	  
Figure 2. Antibody and cellular responses following multi-component prime-boost 667	  
vaccination regimens. 668	  
BALB/c mice (n = 8 per group) were intramuscularly immunised in various prime-boost 669	  
regimens, with sera and vaginal wash collected two weeks after final boost. MOMP-specific 670	  
IgG concentrations were measured in serum (A) and vaginal washes (B), expressed as the 671	  
Regimen d0 d21 d42 d63 d84 
DDDAM DNA DNA DNA HuAd5 MVA 
DDDA DNA DNA DNA HuAd5  
DDDM DNA DNA DNA MVA  
DDD DNA DNA DNA   
AM HuAd5 MVA    
DAMP DNA HuAd5 MVA Protein   
AMPP HuAd5 MVA Protein  Protein   
DDPP DNA DNA Protein  Protein   
APP HuAd5 Protein  Protein    
PPP Protein  Protein  Protein    
PP Protein  Protein     
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mean + SEM concentrations. (C) Serum MOMP-specific IgG2a and IgG1 isotype 672	  
concentrations were measured by ELISA, and the mean + SEM IgG2a:IgG1 ratios plotted. 673	  
The dotted line indicates the IgG2a:IgG1 ratio of 1, demonstrating Th1-skewing above this 674	  
line or Th2-skewing below it. (D) Serum antibody avidity was measured by MOMP-specific 675	  
IgG ELISA with non-reducing (H2O) and reducing (8 M urea) washes after sample addition. 676	  
Results are shown as percentage (%) change in binding (reducing OD 650 /non-reducing OD x 100). IgG 677	  
concentrations, avidities and IgG2a:IgG1 ratio represented as group means and SEM. (E) 678	  
Vaccinated BALB/c mice (n = 8 per group) were sacrificed one-week post-final 679	  
immunisation and splenocytes assessed by IFN-γ ELISpot for MOMP-reactive T cells 680	  
stimulated by a peptide pool consisting of 15-mers overlapping by 11 amino acids. Data 681	  
expressed as group medians (+ interquartile range) (SFU/million antigen stimulated cells). * 682	  
p ≤ 0.05 (yellow), ** p ≤ 0.005 (orange), *** p ≤ 0.0005 (red) and **** p ≤ 0.0001 (dark red) 683	  
by one-way ANOVA with Bonferroni’s multiple comparison post-test on logged values (A-684	  
D) and by Kruskal-Wallis with Dunn’s multiple comparison test (E). 685	  
Figure 3. Prime-boost vaccine regimens induce comparable immune responses in both 686	  
BALB/c and B6C3F1 mouse strains.  687	  
MOMP-specific IgG concentrations were measured in serum (A) and vaginal washes (B) for 688	  
both BALB/c and B6C3F1 vaccinated mice (n = 8 per group), expressed as individual 689	  
concentrations with bars representing the means. (C) Serum MOMP-specific IgG2a and IgG1 690	  
isotype concentrations were measured by ELISA for both BALB/c and B6C3F1 vaccinated 691	  
mice (n = 5-8 per group), and individual points and bars representing the means IgG2a:IgG1 692	  
ratios plotted. The dotted line indicates the IgG2a:IgG1 ratio of 1, demonstrating Th1-693	  
skewing above this line or Th2-skewing below it. (D) Splenocytes were assessed by IFN-γ 694	  
ELISpot for MOMP-reactive T cells stimulated by a peptide pool consisting of 15-mers 695	  
overlapping by 11 amino acids for both vaccinated BALB/c and B6C3F1 mice. Data 696	  
expressed as individual values with bars representing group medians (+ interquartile range) 697	  
(SFU/million antigen stimulated cells). 698	  
Figure 4. The DAMP vaccine regimen enhances the clearance of intravaginal C. 699	  
trachomatis in BALB/c and B6C3F1 mice, in a CD4+ T cell dependent manner.  700	  
Six weeks after the final vaccination and 1 week after 2 mg/mouse subcutaneous Depo-701	  
Provera treatment, BALB/c and B6C3F1 mice (n = 7 to 10 per group) were infected 702	  
intravaginally with 4x105 IFU of C. trachomatis D/UW-3/Cx. The vaginal vault of mice were 703	  
sampled using individual swabs at day 3 ((A) BALB/c; (B) B6C3F1) after challenge, and 704	  
vaginal Chlamydial loads quantified by infection assay and immunoflorescent microscopy. 705	  
The fold reduction in median Chlamydial load compared to naïve BALB/c (A) and B6C3F1 706	  
(B) mice at day 3 after infection is also represented. (C) B6C3F1 mice (n = 8 per group) were 707	  
immunised with the DAMP regimen or left unvaccinated and subsequently depleted of CD4+ 708	  
T cells by i.p. injections of 500 µg/mouse of anti-mouse CD4 monoclonal antibody (clone 709	  
GK1.5) on days -1 and +1 with respect to day of challenge day 0. C. trachomatis load was 710	  
measured in the vaginal vault at day 3 after infection. Individual and median values are 711	  
represented. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 2-tailed Mann-Whitney U test.  712	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